Cargando…
Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis
Amebiasis is a neglected tropical disease which is caused by the protozoan parasite Entamoeba histolytica. This disease is one of the leading causes of diarrhea globally, affecting largely impoverished residents in developing countries. Amebiasis also remains one of the top causes of gastrointestina...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943716/ https://www.ncbi.nlm.nih.gov/pubmed/33718258 http://dx.doi.org/10.3389/fcimb.2020.628257 |
_version_ | 1783662549025161216 |
---|---|
author | Shrivastav, Manish T. Malik, Zainab Somlata, |
author_facet | Shrivastav, Manish T. Malik, Zainab Somlata, |
author_sort | Shrivastav, Manish T. |
collection | PubMed |
description | Amebiasis is a neglected tropical disease which is caused by the protozoan parasite Entamoeba histolytica. This disease is one of the leading causes of diarrhea globally, affecting largely impoverished residents in developing countries. Amebiasis also remains one of the top causes of gastrointestinal diseases in returning international travellers. Despite having many side effects, metronidazole remains the drug of choice as an amebicidal tissue-active agent. However, emergence of metronidazole resistance in pathogens having similar anaerobic metabolism and also in laboratory strains of E. histolytica has necessitated the identification and development of new drug targets and therapeutic strategies against the parasite. Recent research in the field of amebiasis has led to a better understanding of the parasite’s metabolic and cellular pathways and hence has been useful in identifying new drug targets. On the other hand, new molecules effective against amebiasis have been mined by modifying available compounds, thereby increasing their potency and efficacy and also by repurposing existing approved drugs. This review aims at compiling and examining up to date information on promising drug targets and drug molecules for the treatment of amebiasis. |
format | Online Article Text |
id | pubmed-7943716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79437162021-03-11 Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis Shrivastav, Manish T. Malik, Zainab Somlata, Front Cell Infect Microbiol Cellular and Infection Microbiology Amebiasis is a neglected tropical disease which is caused by the protozoan parasite Entamoeba histolytica. This disease is one of the leading causes of diarrhea globally, affecting largely impoverished residents in developing countries. Amebiasis also remains one of the top causes of gastrointestinal diseases in returning international travellers. Despite having many side effects, metronidazole remains the drug of choice as an amebicidal tissue-active agent. However, emergence of metronidazole resistance in pathogens having similar anaerobic metabolism and also in laboratory strains of E. histolytica has necessitated the identification and development of new drug targets and therapeutic strategies against the parasite. Recent research in the field of amebiasis has led to a better understanding of the parasite’s metabolic and cellular pathways and hence has been useful in identifying new drug targets. On the other hand, new molecules effective against amebiasis have been mined by modifying available compounds, thereby increasing their potency and efficacy and also by repurposing existing approved drugs. This review aims at compiling and examining up to date information on promising drug targets and drug molecules for the treatment of amebiasis. Frontiers Media S.A. 2021-02-24 /pmc/articles/PMC7943716/ /pubmed/33718258 http://dx.doi.org/10.3389/fcimb.2020.628257 Text en Copyright © 2021 Shrivastav, Malik and Somlata http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Shrivastav, Manish T. Malik, Zainab Somlata, Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis |
title | Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis |
title_full | Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis |
title_fullStr | Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis |
title_full_unstemmed | Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis |
title_short | Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis |
title_sort | revisiting drug development against the neglected tropical disease, amebiasis |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943716/ https://www.ncbi.nlm.nih.gov/pubmed/33718258 http://dx.doi.org/10.3389/fcimb.2020.628257 |
work_keys_str_mv | AT shrivastavmanisht revisitingdrugdevelopmentagainsttheneglectedtropicaldiseaseamebiasis AT malikzainab revisitingdrugdevelopmentagainsttheneglectedtropicaldiseaseamebiasis AT somlata revisitingdrugdevelopmentagainsttheneglectedtropicaldiseaseamebiasis |